SNP 614
Alternative Names: SNP-614Latest Information Update: 22 Apr 2023
At a glance
- Originator SciNeuro Pharmaceuticals
- Class Antiparkinsonians; Antisense oligonucleotides
- Mechanism of Action Gene silencing; LRRK2 protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 12 Apr 2023 Preclinical trials in Parkinson's disease in China (Parenteral) (SciNeuro Pharmaceuticals pipeline, April 2023)
- 12 Apr 2023 Early research in Parkinson's disease in China (Parenteral) before August 2022
- 27 Mar 2023 Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enters into a research and option agreement to develop next-generation antisense oligonucleotide (ASO) therapies for the treatment of central nervous system diseases